Skip to main content

2013 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
12/20/13Bard to Present at J.P. Morgan Healthcare Conference
MURRAY HILL, N.J.--(BUSINESS WIRE)--Dec. 20, 2013-- C. R. Bard, Inc. (NYSE:BCR) today announced that it will present at the J.P. Morgan Healthcare Conference in San Francisco, California on January 14, 2014. Timothy M. Ring, chairman and chief executive officer, will discuss the Company in a presentation scheduled to begin at 2:30 PM Pacific Standard Time. A live webcast of Bard's presentation and question and answer session will be access... 
Printer Friendly Version
12/11/13Bard Declares Quarterly Dividend
MURRAY HILL, N.J.--(BUSINESS WIRE)--Dec. 11, 2013-- The Board of Directors of C. R. Bard, Inc. (NYSE:BCR) today declared a regular quarterly dividend of 21 cents per share on Bard's common stock. The current indicated annual dividend rate is 84 cents per share. The dividend is payable on January 31, 2014 to shareholders of record at the close of business on January 21, 2014. C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, ... 
Printer Friendly Version
11/25/13Bard Submits Final PMA Module to the FDA for the Lutonix Drug-Coated Balloon
MURRAY HILL, N.J.--(BUSINESS WIRE)--Nov. 25, 2013-- C. R. Bard, Inc. (NYSE: BCR) today announced that its Lutonix technology center submitted the final module of the pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) to support approval for the Lutonix® Drug-Coated PTA Dilatation Catheter (DCB). The Lutonix® DCB is being clinically evaluated in the global, multicenter LEVANT 2 randomized clinical trial (http://www.levant... 
Printer Friendly Version
11/20/13Bard to Present at Piper Jaffray Healthcare Conference
MURRAY HILL, N.J.--(BUSINESS WIRE)--Nov. 20, 2013-- C. R. Bard, Inc. (NYSE:BCR) today announced that it will present at the Piper Jaffray Healthcare Conference in New York City on December 4, 2013. Christopher S. Holland, senior vice president and chief financial officer, will discuss the Company in a presentation scheduled to begin at 9:30 AM Eastern Standard Time (EST). A live audio webcast of Bard's presentation and question and answer ... 
Printer Friendly Version
10/30/13Lutonix Six-Month Results Presented on First IDE Trial for Drug-Coated Balloons
MURRAY HILL, N.J.--(BUSINESS WIRE)--Oct. 30, 2013-- Today at the Transcatheter Cardiovascular Therapies (TCT) conference in San Francisco, California, Kenneth Rosenfield, M.D., Section Head for Vascular Medicine and Intervention, Massachusetts General Hospital and LEVANT 2 Co-Primary Investigator, is presenting information related to the study design, demographics, and six-month follow-up results from the patients randomized in the LEVANT 2 Lutonix Drug-... 
Printer Friendly Version
10/29/13Bard to Present at Credit Suisse Healthcare Conference
MURRAY HILL, N.J.--(BUSINESS WIRE)--Oct. 29, 2013-- C. R. Bard, Inc. (NYSE:BCR) today announced that it will present at the Credit Suisse Healthcare Conference in Phoenix, Arizona on November 12, 2013. Timothy M. Ring, chairman and chief executive officer, will discuss the Company in a presentation scheduled to begin at 3:30 PM Mountain Standard Time (MST). A live audio webcast of Bard's presentation and question and answer session will be... 
Printer Friendly Version
10/22/13Bard Announces Third Quarter Results
MURRAY HILL, N.J.--(BUSINESS WIRE)--Oct. 22, 2013-- C. R. Bard, Inc. (NYSE: BCR) today reported 2013 third quarter financial results. Third quarter 2013 net sales were $758.0 million, an increase of 5 percent over the prior-year period on a reported basis. Excluding the impact of foreign exchange, third quarter 2013 net sales increased 4 percent over the prior-year period. For the third quarter 2013, net sales in the U.S. were $500.3 million, ... 
Printer Friendly Version
10/10/13First of Its Kind Study Design Raises the Bar for Scientific Rigor in Drug-Coated Balloons
MURRAY HILL, N.J.--(BUSINESS WIRE)--Oct. 10, 2013-- Today at the Vascular Interventional Advances (VIVA) meeting in Las Vegas, Nevada, Professor Dierk Scheinert, M.D., Head of the Department of Medicine, Angiology and Cardiology, Park-Krankenhaus Hospital, Leipzig, Germany and LEVANT 2 Co-Primary Investigator, is presenting information related to the LEVANT 2 Lutonix Drug-Coated Balloon (DCB) study design. Unlike recent studies in Peripher... 
Printer Friendly Version
10/09/13Bard Declares Quarterly Dividend
MURRAY HILL, N.J.--(BUSINESS WIRE)--Oct. 9, 2013-- The Board of Directors of C. R. Bard, Inc. (NYSE:BCR) today declared a regular quarterly dividend of 21 cents per share on Bard's common stock. The current indicated annual dividend rate is 84 cents per share. The dividend is payable on November 1, 2013 to shareholders of record at the close of business on October 21, 2013. C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, N... 
Printer Friendly Version
10/01/13Bard to Host Earnings Conference Call on October 22, 2013
MURRAY HILL, N.J.--(BUSINESS WIRE)--Oct. 1, 2013-- C. R. Bard, Inc. (NYSE: BCR) today announced that it will host a conference call on Tuesday, October 22, 2013 at 5:00 PM EDT, to discuss the company’s third quarter 2013 operating results, and to provide financial guidance for the fourth quarter of 2013. Bard is scheduled to issue an earnings press release after the market closes on October 22, 2013. A live audio webcast of Bard's investor... 
Printer Friendly Version
09/27/13Upcoming Presentations Related to the Lutonix Drug-Coated Balloon LEVANT 2 Trial
MURRAY HILL, N.J.--(BUSINESS WIRE)--Sep. 27, 2013-- C. R. Bard, Inc. (NYSE: BCR) today announced two upcoming presentations related to the company’s Lutonix Drug-Coated Balloon (DCB) LEVANT 2 Trial. The first presentation will be at the Vascular Interventional Advances (VIVA) meeting in Las Vegas, Nevada on October 10, 2013. In this presentation, Professor Dierk Scheinert, M.D., Head of the Department of Medicine, Angiology and Cardiology,... 
Printer Friendly Version
09/04/13Bard Announces Agreement to Acquire Rochester Medical, Inc.
MURRAY HILL, N.J.--(BUSINESS WIRE)--Sep. 4, 2013-- C. R. Bard, Inc. (NYSE:BCR) today announced that it has entered into a definitive agreement to acquire Rochester Medical, Inc. (NASDAQ:ROCM), a leading developer and supplier of silicone urinary incontinence and urine drainage products, for a purchase price of $20 per share, or approximately $262 million in the aggregate to be paid at closing, expected to occur later this year. This transaction is struct... 
Printer Friendly Version
09/03/13Bard to Host Conference Call on September 4, 2013
MURRAY HILL, N.J.--(BUSINESS WIRE)--Sep. 3, 2013-- C. R. Bard, Inc. (NYSE:BCR) today announced that it will host a conference call on Wednesday, September 4, 2013 at 8:30 AM EDT, to discuss recent business development activity. A live audio webcast of Bard's investor conference call will be accessible to all investors through Bard’s website at http://investorrelations.crbard.com. The recommended browser is Internet Explorer 7+. Users also... 
Printer Friendly Version
08/20/13Bard to Present at Morgan Stanley Global Healthcare Conference
MURRAY HILL, N.J.--(BUSINESS WIRE)--Aug. 20, 2013-- C. R. Bard, Inc. (NYSE: BCR) today announced that it will present at the Morgan Stanley Global Healthcare Conference in New York City on September 10, 2013. Timothy M. Ring, chairman and chief executive officer, will discuss the Company in a presentation scheduled to begin at 11:10 AM Eastern Daylight Time. A live audio webcast of Bard's presentation and question and answer session will b... 
Printer Friendly Version
08/19/13Bard Announces Agreement to Acquire Medafor, Inc.
MURRAY HILL, N.J.--(BUSINESS WIRE)--Aug. 19, 2013-- C. R. Bard, Inc. (NYSE: BCR) today announced that it has entered into a definitive agreement to acquire privately-held Medafor, Inc., a leading developer and supplier of plant based hemostatic agents for the purchase price of $200 million paid at closing, expected to occur later this year, and future contingent payments up to an additional $80 million based on specific revenue-based milestones through J... 
Printer Friendly Version
07/23/13Bard Announces Second Quarter Results
MURRAY HILL, N.J.--(BUSINESS WIRE)--Jul. 23, 2013-- C. R. Bard, Inc. (NYSE: BCR) today reported 2013 second quarter financial results. Second quarter 2013 net sales were $759.9 million, an increase of 2 percent over the prior-year period on a reported basis. Excluding the impact of foreign exchange, second quarter 2013 net sales increased 3 percent over the prior-year period. For the second quarter 2013, net sales in the U.S. were $497.6 million,... 
Printer Friendly Version
07/09/13Bard to Host Earnings Conference Call on July 23, 2013
MURRAY HILL, N.J.--(BUSINESS WIRE)--Jul. 9, 2013-- C. R. Bard, Inc. (NYSE: BCR) today announced that it will host a conference call on Tuesday, July 23, 2013 at 5:00 PM EDT, to discuss the company’s second quarter 2013 operating results, and to provide financial guidance for the third quarter of 2013. Bard is scheduled to issue an earnings press release after the market closes on July 23, 2013. A live audio webcast of Bard's investor conference w... 
Printer Friendly Version
06/28/13Bard to Divest Electrophysiology Business
MURRAY HILL, N.J.--(BUSINESS WIRE)--Jun. 28, 2013-- C. R. Bard, Inc. (NYSE: BCR) today announced that it has entered into an agreement to sell certain assets of its Electrophysiology division to Boston Scientific Corporation (NYSE-BSX) for $275 million in cash. The transaction is expected to close in 2013, subject to certain regulatory and customary closing conditions. Bard Electrophysiology division, located in Lowell, Massachusetts, manu... 
Printer Friendly Version
06/12/13Bard Increases Quarterly Dividend
MURRAY HILL, N.J.--(BUSINESS WIRE)--Jun. 12, 2013-- The Board of Directors of C. R. Bard, Inc. (NYSE: BCR) today increased the quarterly dividend on Bard's common stock by 5 percent, to 21 cents per share. The dividend is payable on August 2, 2013 to shareholders of record at the close of business on July 22, 2013. C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, N.J., is a leading multinational developer, manufacturer and ... 
Printer Friendly Version
06/12/13Bard Announces $500 Million Share Repurchase Authorization
MURRAY HILL, N.J.--(BUSINESS WIRE)--Jun. 12, 2013-- The Board of Directors of C. R. Bard, Inc. (NYSE: BCR) today authorized the repurchase of up to $500 million of the company’s common stock. This is in addition to approximately $30 million remaining under the June 2012 authorization. Share repurchases will be made from time-to-time in the open market or through privately negotiated transactions. C. R. Bard, Inc. (www.crbard.com), headquar... 
Printer Friendly Version
06/04/13Bard Announces First Patient Enrolled in Lutonix Below the Knee (BTK) Clinical Trial
First of its kind global clinical trial to evaluate Lutonix® Drug Coated Balloon (DCB) technology to treat restenosis and occlusions for below the knee peripheral arterial disease MURRAY HILL, N.J.--(BUSINESS WIRE)--Jun. 4, 2013-- C. R. Bard, Inc. (NYSE: BCR) today announced the enrollment of the first patient into the Lutonix Below the Knee (BTK) Clinical Trial at The Cardiac and Vascular Institute in Gainesville, Florida. The purpose of this... 
Printer Friendly Version
05/03/13Bard to Host Investor Conference
MURRAY HILL, N.J.--(BUSINESS WIRE)--May. 3, 2013-- C. R. Bard, Inc. (NYSE: BCR) today announced that it will hold an investor conference on Monday, June 3, 2013 at 4:30 PM EDT in New York City. The conference will be hosted by Timothy M. Ring, chairman and chief executive officer, and will include an update on Bard's product pipeline. A live audio webcast of Bard's investor conference will be accessible to all investors through Bard’s webs... 
Printer Friendly Version
04/23/13Bard Announces First Quarter Results
Diluted EPS of $1.08, $1.44 on Adjusted Basis MURRAY HILL, N.J.--(BUSINESS WIRE)--Apr. 23, 2013-- C. R. Bard, Inc. (NYSE: BCR) today reported 2013 first quarter financial results. First quarter 2013 net sales were $740.3 million, an increase of 1 percent over the prior-year period on a reported basis. Excluding the impact of foreign exchange, first quarter 2013 net sales also increased 1 percent over the prior-year period. For the firs... 
Printer Friendly Version
04/17/13Bard Declares Quarterly Dividend
MURRAY HILL, N.J.--(BUSINESS WIRE)--Apr. 17, 2013-- The Board of Directors of C. R. Bard, Inc. (NYSE: BCR) today declared a regular quarterly dividend of 20 cents per share on Bard's common stock. The current indicated annual dividend rate is 80 cents per share. The dividend is payable on May 10, 2013 to shareholders of record at the close of business on April 29, 2013. C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, N.J.,... 
Printer Friendly Version
04/08/13Bard to Host Earnings Conference Call on April 23, 2013
MURRAY HILL, N.J.--(BUSINESS WIRE)--Apr. 8, 2013-- C. R. Bard, Inc. (NYSE: BCR) today announced that it will host a conference call on Tuesday, April 23, 2013 at 5:00 PM EDT, to discuss the company’s first quarter 2013 operating results, and to provide financial guidance for the second quarter of 2013. Bard is scheduled to issue an earnings press release after the market closes on April 23, 2013. A live audio webcast of Bard's investor con... 
Printer Friendly Version
03/06/13Bard to Present at Barclays Global Healthcare Conference
MURRAY HILL, N.J.--(BUSINESS WIRE)--Mar. 6, 2013-- C. R. Bard, Inc. (NYSE: BCR) today announced that it will present at the Barclays Global Healthcare Conference in Miami, Florida on March 13, 2013. Timothy M. Ring, chairman and chief executive officer, will discuss the Company in a presentation scheduled to begin at 11:15 AM EDT. A live audio webcast of Bard's presentation and question and answer session will be accessible to all investors t... 
Printer Friendly Version
02/25/13Bard to Present at Raymond James Institutional Investor Conference
MURRAY HILL, N.J.--(BUSINESS WIRE)--Feb. 25, 2013-- C. R. Bard, Inc. (NYSE: BCR) today announced that it will present at the Raymond James Institutional Investor Conference in Orlando, Florida on March 4, 2013. Christopher S. Holland, senior vice president and chief financial officer, will discuss the Company in a presentation scheduled to begin at 4:35 PM Eastern Standard Time. A live audio webcast of Bard's presentation and question and ans... 
Printer Friendly Version
02/14/13Bard to Present at Citi 2013 Global Healthcare Conference
MURRAY HILL, N.J.--(BUSINESS WIRE)--Feb. 14, 2013-- C. R. Bard, Inc. (NYSE: BCR) today announced that it will present at the Citi 2013 Global Healthcare Conference in New York City on February 27, 2013. Timothy M. Ring, chairman and chief executive officer, will discuss the Company in a presentation scheduled to begin at 2:15 PM Eastern Standard Time. A live audio webcast of Bard's presentation and question and answer session will be a... 
Printer Friendly Version
01/31/13Bard Announces Fourth Quarter Results Diluted EPS of $1.52, $1.70 on Adjusted Basis
MURRAY HILL, N.J.--(BUSINESS WIRE)--Jan. 31, 2013-- C. R. Bard, Inc. (NYSE: BCR) today reported 2012 fourth quarter financial results. Fourth quarter 2012 net sales were $762.6 million, an increase of 1 percent over the prior-year period on an as-reported basis. Excluding the impact of foreign exchange, fourth quarter 2012 net sales increased 2 percent over the prior-year period. For the fourth quarter 2012, net sales in the U.S. were $498.1 ... 
Printer Friendly Version
01/07/13Bard to Host Earnings Conference Call on January 31, 2013
MURRAY HILL, N.J.--(BUSINESS WIRE)--Jan. 7, 2013-- C. R. Bard, Inc. (NYSE: BCR) today announced that it will host a conference call on Thursday, January 31, 2013 at 4:30 PM EST, to discuss the company’s operating results for the fourth quarter and full year 2012, and to provide financial guidance for 2013. Bard is scheduled to issue an earnings press release after the market closes on January 31, 2013. A live audio webcast of Bard's in... 
Printer Friendly Version
Print Page Print Page | E-mail Page E-mail Page